UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/797,747	03/10/2004`	Frank Daniel Long	1341-3	3427
23869 7590 08/13/2007 HOFFMANN & BARON, LLP 6900 JERICHO TURNPIKE			EXAMINER	
			YU, GINA C	
SYOSSET, NY 11791			ART UNIT	PAPER NUMBER
		•	1617	
	•			
			MAIL DATE	DELIVERY MODE
			08/13/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
·						
Office Action Summary	10/797,747	LONG ET AL.				
onice Action Guilliary	Examiner	Art Unit				
The MAIL INC DATE of this communication and	Gina C. Yu	1617				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on <u>02 August 2007</u> .						
, ,—	This action is FINAL . 2b)⊠ This action is non-final.					
	· -					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-124</u> is/are pending in the application.						
4a) Of the above claim(s) <u>13-22 and 73-124</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-12 and 23-72</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers	.•					
	r					
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
· · ·						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
·		•				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D 5) Notice of Informal F					
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>7/8/04</u> .	6) Other:	and the manual of the same of				

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

Claims 13-22, 73-124 are withdrawn from further consideration pursuant to 37

CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on August 2, 2007.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4-9, 51-54 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The term "rich" in claims 4, 5, and 51-54 is a relative term which renders the claim indefinite. The term "rich" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention.

Claim 5 is vague and indefinite, as it is not clear what "a specific type of collagen" is.

Claim 6 is vague and indefinite, as the term "specific ratios" is not defined. recites "different isolates", combinations of "different eggshell membrane powders". It is not clear what applicants mean by "different" in the present claim. Does applicant mean that different types of eggshells are used?

Art Unit: 1617

The remaining claims are rejected as depending

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-8, 10-12, 23-57, 60-72 are rejected under 35 U.S.C. 102(b) as being anticipated by Matsui (JP 05-178735 A, English translation).

Matsui discloses cosmetic compositions comprising soluble eggshell membrane and mucopolysaccharide. See Translation, Tables; instant claims 1, 23, 49, 61-64. The reference teaches that the soluble eggshell membrane is obtained by solubilizing the membrane with an acid agent, alkali agent. See [0008]; instant claims 2, 3, 50. The reference teaches that mucopolysaccharide of the present invention consists of N-acetyl-D-glucosamine, hyaluronic acid, chondroitin sulfate, etc, extracted from a crest, umbilical cord, eyeball, skin, and cartilaginous tissue. See [0007]. Since the claimed limitations of eggshell membrane is not distinct from the prior art material, it is viewed that the prior art eggshell membrane also inherently contains the components of instant claims 4-12, 28-36, 51-57. Formulation types include lotion, cream, powder, facial pack, etc. See [0011]; instant claims 23-25, 37, 46, 60, 65-71. For the weight amount of the carrier, see the formulations of Tables. See instant claims 38-42. The same paragraph of the reference also discloses the additives of instant claim 27. The reference teaches that soluble eggshell membrane renders beautifying effects. See instant claims 1, 26.

Art Unit: 1617

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 9, 58 and 59 are rejected under 35 U.S.C. 103(a) as being unpatentable over Matsui as applied to Claims 1-8, 10-12, 23-57, 60-72 as above.

While the reference does not disclose with a sufficient specificity a formulation comprising a combination of different isolate and/or powders as required by instant claims, the reference does indicate that the eggshell membranes are prepared by using different agents, and from different sources.

It would have been obvious to one of ordinary skill in the art at the time of the present invention to modify the teaching of Matsui by combining the eggshell membrane materials of the different types, as motivated by the reference, in expectation of making

Art Unit: 1617

a product having similar or enhanced cosmetic properties. The idea for combining compounds each of which is known to be useful for the same purpose, in order to form a composition which is to be used for the same purpose, flows logically from their having been used individually in the prior art. See In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). As shown by the recited teachings, the instant claims define nothing more than the concomitant use of eggshell membrane materials in cosmetic compositions. It would follow that the recited claims define prima facie obvious subject matter.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Art Unit: 1617

Claims 1-12 and 23-72 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-29 of U.S. Patent No. 6,946,551 B2.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the '551 patent claims a method of making the composition which is claimed in the present application.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gina C. Yu whose telephone number is 571-272-8605. The examiner can normally be reached on Monday through Friday, from 8:00AM until 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/797,747 Page 7

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Gina C. Yu

Patent Examiner